Targeted therapies: Using β-blockers to inhibit breast cancer progression

Desmond G Powe; Frank Entschladen

doi:10.1038/nrclinonc.2011.123

Targeted therapies: Using β-blockers to inhibit breast cancer progression

Nat Rev Clin Oncol. 2011 Aug 2;8(9):511-2. doi: 10.1038/nrclinonc.2011.123.

Authors

Desmond G Powe¹, Frank Entschladen

Affiliation

¹ Department of Cellular Pathology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, UK. des.powe@nottingham.ac.uk

PMID: 21808268
DOI: 10.1038/nrclinonc.2011.123

Abstract

Three recent population studies have translated laboratory investigations into a clinical setting and concur in presenting evidence that suggest a dramatic new role for β-blockers in reducing metastases, tumor recurrence and specific mortality in breast cancer. Should we be skeptical about these controversial findings?

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adrenergic beta-Antagonists / pharmacology*
Adrenergic beta-Antagonists / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / mortality*
Female
Humans

Substances

Adrenergic beta-Antagonists